CAR T-Cell Therapy for Non-Hodgkin Lymphoma Market Set for Robust Growth at a CAGR of ~7% Through 2036, Driven by Expanding Indications and Clinical Adoption | DelveInsight

Summary

Market research report indicates CAR T-cell therapy for non-Hodgkin lymphoma market is expected to grow at approximately 7% CAGR through 2036, driven by expanding clinical indications and increasing adoption of advanced cell-based treatments over conventional chemo-immunotherapy.